mCureX Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Out of Business

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Out of Business

mCureX General Information

Description

Developer of mRNA-based biopharmaceuticals designed for infectious disease prevention and targeted therapeutic intervention purposes. The company's platform leverages proprietary nucleotide modification and molecular design technologies to produce rapid-response vaccine candidates and therapeutic formulations targeting COVID-19, influenza, cancer, and genetic disorders, enabling pharmaceutical partners and healthcare providers to accelerate clinical development and address emerging health threats.

Contact Information

Website
www.mcurextx.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Sampyeong-dong, Office B Building, 6th Floor
  • 225-15 Pangyo Station-ro, Bundang-gu
  • Seongnam, Gyeonggi 13494
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Sampyeong-dong, Office B Building, 6th Floor
  • 225-15 Pangyo Station-ro, Bundang-gu
  • Seongnam, Gyeonggi 13494
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

mCureX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 09-Aug-2026 Completed Out of Business
2. Secondary Transaction - Private 01-Jul-2025 Completed Generating Revenue
1. Seed Round 01-Jun-2021 $5.79M $5.79M Completed Generating Revenue
To view mCureX’s complete valuation and funding history, request access »

mCureX Patents

  • 2

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

mCureX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024014770-A1 Modified rna for preparing mrna vaccine and therapeutic agent Inactive 14-Jul-2022
WO-2023195566-A1 Rna vaccine for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection Inactive 07-Apr-2022

mCureX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

mCureX FAQs

  • When was mCureX founded?

    mCureX was founded in 2021.

  • Where is mCureX headquartered?

    mCureX is headquartered in Seongnam, South Korea.

  • What is the size of mCureX?

    mCureX has 2 total employees.

  • What industry is mCureX in?

    mCureX’s primary industry is Drug Discovery.

  • Is mCureX a private or public company?

    mCureX is a Private company.

  • What is mCureX’s current revenue?

    The current revenue for mCureX is .

  • How much funding has mCureX raised over time?

    mCureX has raised $5.79M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process